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Anaphylatoxins are produced upon
complement activation and are well-
known pro-inflammatory molecules. van
den Broek and colleagues demonstrate
that anaphylatoxins are produced within
a tumor after radiotherapy by immune
cells, support tumor-specific immunity,
and are essential to therapeutic efficacy.
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Radiotherapy induces DNA damage and cell death,
but recent data suggest that concomitant immune
stimulation is an integral part of the therapeutic ac-
tion of ionizing radiation. It is poorly understood
how radiotherapy supports tumor-specific immunity.
Here we report that radiotherapy induced tumor cell
death and transiently activated complement both in
murine and human tumors. The local production of
pro-inflammatory anaphylatoxins C3a and C5a was
crucial to the tumor response to radiotherapy and
concomitant stimulation of tumor-specific immunity.
Dexamethasone, a drug frequently given during
radiotherapy, limited complement activation and
the anti-tumor effects of the immune system. Overall,
our findings indicate that anaphylatoxins are key
players in radiotherapy-induced tumor-specific im-
munity and the ensuing clinical responses.
INTRODUCTION
It is now well accepted that the immune system can control
tumors (Schreiber et al., 2011). For example, there is a positive
correlation between tumor infiltration by effector T cells and sur-
vival (Fridman et al., 2011), and the risk to develop cancer is
increased in immunosuppressed patients (Dunn et al., 2006),
and dormant tumors are kept in check by the adaptive immune
system (Koebel et al., 2007). Despite the presence of tumor-spe-
cific immunity in many cancer patients, complete rejection of
clinically apparent tumors by the immune system is rare, pre-
sumably due to mechanisms that locally inhibit tumor-specific
protective immunity (Schreiber et al., 2011). The clinical efficacy
of so-called checkpoint blockade, antibodies that target co-
inhibitory molecules such as CTLA-4 or PD-1, underscores the
potential of tumor-specific immunity (McDermott and Atkins,
2013; Mellman et al., 2011).Radiotherapy is a standard treatment for cancer that induces
irreversible damage to DNA, thus targeting mainly rapidly
dividing cells (Prise and O’Sullivan, 2009). Although radiotherapy
was considered an immunosuppressive treatment (Merrick et al.,
2005), there is accumulating evidence that it supports local
tumor-specific immunity (Apetoh et al., 2007; Matsumura et al.,
2008) and, in fact, that immune activation might be an integral
part of radiotherapy (Formenti and Demaria, 2012; Gupta et al.,
2012; Ma et al., 2010; Sharma et al., 2013). This is clinically rele-
vant because tumor-specific immunity can target dormant
lesions (Postow et al., 2012) that are presumably insensitive to
radiotherapy. Several studies have addressed the question
of how radiotherapy supports tumor-specific immunity, and
various factors were suggested, including increased presence
or function of tumor-infiltrating CD8+ T cells (Gupta et al.,
2012; Lugade et al., 2005; Takeshima et al., 2010), type I inter-
feron (IFN) resulting in enhanced antigen cross-presentation
(Burnette et al., 2011; Fuertes et al., 2011), increased expression
of major histocompatibility complex (MHC) class I glycoproteins
and tumor-associated antigens (Reits et al., 2006), and matura-
tion of tumor-associated dendritic cells (DCs) (Gupta et al.,
2012), however, an initial event has not been identified.
We therefore performed an unbiased analysis of immune
response-related transcripts after radiotherapy in a preclinical
model and noted a strong and transient upregulation of genes
associated with the complement pathway. This was unexpected
as complement was described as tumor-promoting (Markiewski
et al., 2008; Pio et al., 2014), although other studies have shown
that complement supports adaptive immunity (Farrar and Sacks,
2014; Kopf et al., 2002; Lalli et al., 2007; Liszewski et al., 2013;
Strainic et al., 2013). Becauseweobserved similar changes in hu-
man tumor samples, we investigated the impact of complement
on the anti-tumor immune response following radiotherapy.
RESULTS
Radiotherapy Induces Complement Activation
To identify the initial event in radiotherapy-induced tumor-spe-
cific immunity, we performed an unbiased analysis of immuneImmunity 42, 767–777, April 21, 2015 ª2015 Elsevier Inc. 767
Figure 1. Radiotherapy Results in Transient Upregulation and Acti-
vation of Complement in Murine and Human Tumors
(A–E) Mice were injected with B16F10-OVA cells and received radiotherapy
12 days later. (A) Tumor growth curves, (n = 5 mice per group). Representative
data from three independent experiments are shown. (B) Tumor weight
(day 20). (C) Heatmaps of transcripts were created using the log2 value of
the fold increase of irradiated compared to untreated tumors at different
time points after radiotherapy, (n = 6 mice per time point). Representative data
from two independent experiments are shown. (D) Relative expression of C3
mRNA in tumors at different time points after radiotherapy. The data show the
mean ± SD of triplicates from three independent analyses. Radiotherapy, RT.
(E) Immunofluorescence of irradiated and untreated tumors. Sections were
stained with an antibody recognizing C3b, iC3b, and C3c (green), CD31 for
blood vessels (red), and DAPI (blue). Scale bars represent 100 mm (n = 6 mice
per group). Representative images from two independent experiments are
shown.
(F and G) Patient biopsies were collected before and 24–36 hr after radio-
therapy (1.5–2 Gy; upper panel) or only after radiotherapy (lower panel).
Quantification of complement transcripts by qPCR. Data show the mean ± SD
of triplicates from two independent analyses (upper panel). (G) Quantification
of C3-a and -b subunits by immuno-blot.
Data are shown as mean ± SD. *p < 0.05, **p < 0.005, ***p < 0.0005 by Stu-
dent’s t test (A, B, and F) or two-way ANOVAwith the Bonferroni correction (D).
See also Figure S1.
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with a single dose of 20 Gy significantly reduced progression of
B16F10-OVA tumors in C57BL/6 mice (Figures 1A and 1B).
Because transplantable mouse tumors only allow for a short
therapeutic window, radiotherapy must be applied as a single
high dose (Lugade et al., 2005). To dissect which pathways are
crucial to radiotherapy-induced stimulation of the immune
response, we quantified immune response-related transcripts
in tumors at different time points 4, 24, 96, and 168 hr after local
irradiation (Figures 1C and S1A). We observed an upregulation of
the complement system (represented in this panel only by C3)
and the inflammation cascade at 4 and 24 hr, whereas both path-
ways were downregulated at 96 and 168 hr after irradiation (Fig-
ure 1C). Because 20 Gymight be of limited clinical relevance, we
performed the same analysis 24 hr after irradiation with a single
dose of 5 Gy and observed a similar transcriptional upregulation
(Figure S1B).
C3 is the central protein of the complement cascade at which
all three known pathways (classical, alternative, and lectin)
converge and which gives rise to various bioactive components
(Markiewski and Lambris, 2009). Because complement might be
tumor-promoting (Markiewski et al., 2008; Markiewski and
Lambris, 2009; Pio et al., 2014), we investigated whether radio-
therapy-induced upregulation of complement supported or
antagonized the efficacy of this treatment. We first quantified
four different complement-related transcripts in response to
radiotherapy: C3, C1s, Masp2 and Cfb. The classical and alter-
native pathways are the main pathways induced by radiotherapy
on the transcriptional level (Figures 1D and S1C). Because
NF-kB, JAK, and STAT transcriptional pathways (Chen et al.,
2011; Fukuoka et al., 2013; Hasegawa et al., 2014; Huang
et al., 2002), as well as S100 calcium-binding proteins A8 and
A9 (S100A8, S100A9) (Schonthaler et al., 2013) are involved in
the transcription of complement factors, we analyzed such path-
ways by immuno-blot and found an increased production of
STAT 1, STAT 2, STAT 3, NF-kB, and JAK and increased phos-
phorylation of STAT 2, STAT3, and JAK (Figure S1D) 4 hr, but not
Figure 2. C3a and C5a Are Crucial to the Therapeutic Efficacy of
Radiotherapy
(A) Control and C3/mice were injected with B16F10-OVA cells and received
radiotherapy 13 days later. Growth curves, (n = 5 mice per group). Represen-
tative data from two independent experiments are shown. Radiotherapy, RT.
(B) BALB/c, C3ar1/, C5ar1/, and C3ar1/C5ar1/ were injected with
CT26 cells and received radiotherapy 13 days later. Tumor growth curves
(BALB/c n = 5 mice per group; C3ar1/, C5ar1/, and C3ar1/C5ar1/
n = 8mice per group). Representative data from two independent experiments
are shown.
(C) Mice were injected with B16F10-OVA cells and received radiotherapy
12 days later. SB290157 was administered at 2 mg/kg to block C3aR1 and
anti-C5aR1 mAb 20/70 or an isotype control at 0.6 mg/kg to block C5aR1
(administered every second day starting on day 12 until day 19). (n = 5mice per
group).
Data are shown as the mean ± SD. **p < 0.005, ***p < 0.0005, ****p < 0.00005
by two-way ANOVA with the Bonferroni correction. See also Figure S2.24 hr, after radiotherapy. Transcripts of S100a8 and S100a9
were unaffected (data not shown).
To show that these translated in different complement factor
amounts, we analyzed the tumors prior to and after radiotherapy
by immunofluorescence (Figure S1E) and by immuno-blot (Fig-ure S1F). Because C1q and Factor B are more abundant
compared to mannose-binding lectin C (MBL-C), these results
confirmed our qPCR data (Figure S1C). We analyzed the activa-
tion status of complement and found deposition of fragments
derived from C3 cleavage (C3b, iC3b, and C3c) 24 hr after radio-
therapy in the proximity of (green fluorescence) or associated
with (yellow fluorescence) blood vessels (Figure 1E). Similarly
to C3 cleavage products, we observed C1q and Factor B mainly
associated to blood vessels, whereas MBL-C showed a mark-
edly different pattern of deposition. We obtained similar results
using B16F10 cells, both at the transcriptional (data not shown)
and protein level (Figure S1G). We confirmed radiotherapy-
induced complement activation by immuno-blotting using an
antibody recognizing C3 plus its fragments C3b, C3c, and
C3dg (Figure S1H). Because deposition of C3b, iC3b, and C3c
was not detected at other time points besides 24 hr after radio-
therapy, this suggests that radiotherapy-induced complement
activation is a rapid and transient response.
We analyzed the expression of complement-related tran-
scripts and proteins in paired human tumors that were collected
before and 24–36 hr after a single, low dose of radiotherapy (1.5
or 2 Gy) and detected upregulated expression (Figure 1F) and
activation of complement (Figure 1G). To exclude that taking
the first biopsy prior to radiotherapy rather than radiotherapy
was responsible for complement activation, we analyzed addi-
tional four biopsies that were taken 24–36 hr after irradiation
with 1.5–2 Gy but without previous intervention. The amounts
of complement transcripts were comparable to those after radio-
therapy in the paired samples, excluding this option (Figure 1F).
Together, we found that radiotherapy induces transient, local
production, and activation of the classical and alternative com-
plement pathway in both human and murine tumors.
Therapeutic Efficacy of Radiotherapy Depends on C3a
and C5a
To investigate the impact of complement activation on therapeu-
tic efficacy, we applied radiotherapy to tumor-bearing C3/
mice. Because tumors grew more slowly in C3/ mice (Figures
2A and S2A) (Markiewski et al., 2008; Qing et al., 2012), C3/
and C57BL/6 mice were irradiated at two different time points,
i.e., 13 (Figure 2A) or 17 days (Figure S2B) after tumor injection.
Comparison of C57BL/6 mice irradiated at day 13 (Figure 2A, left
panel) with C3/ mice irradiated at day 17 (Figure S2B, right
panel) shows the response of tumors with a similar size (36–
40 mm2) at the time point of irradiation. Radiotherapy was not
efficient in C3/mice irrespective of the day of therapy (Figures
2A, S2A, and S2B), suggesting that complement activation is
crucial to efficacy.
Anaphylatoxins (C3a and C5a) modulate adaptive immunity
(Schmudde et al., 2013; Strainic et al., 2013). As we observed
higher local amounts of C3a and C5a (Figure S2C) and their
receptors (Figures S2D) upon radiotherapy, we investigated
their role in the response to radiotherapy using C3ar1/,
C5ar1/, and C3ar1/C5ar1/ mice. As these mice were
only available on a BALB/c background, we confirmed that
radiotherapy resulted in local complement activation (Fig-
ure S2E), showing that radiotherapy-induced complement
activation is a general phenomenon independent of the strain
or tumor cell line used. Similar to C3/ mice, C5ar1/,Immunity 42, 767–777, April 21, 2015 ª2015 Elsevier Inc. 769
Figure 3. Radiotherapy-Induced Tumor
Cells Death Activates Complement
(A and B) B16F10-OVA cells were irradiated in vitro
with 20 Gy or left untreated. Serum from C57BL/6
or C3/ mice was added to the cultures immedi-
ately after irradiation and C3 cleavage products
were analyzed 4 and 24 hr later in the supernatants
by immuno-blot using a polyclonal anti-C3 anti-
body (n = 3 mice per group). Representative data
of two independent experiments are shown. (B)
Relative intensities were calculated using Bio1D
software. Radiotherapy, RT.
(C) Ultrastructural analysis of tumor response to
radiotherapy. B16F10-OVA tumors were isolated
from mice prior to and different times after radio-
therapy. Fixed tumor tissue was epon embedded
and analyzed by EM. Shown are images of tumor
tissues before (0 h), 1, 4, and 18 hr after radio-
therapy. Left column, overview; Right column,
zoom-in of region indicated in left image. Bar in-
dicates magnification. N, nucleus; M, mitochon-
drion; black arrow, cell boundaries; F, fat bodies;
C, collagen; *, melanosomes.
(D and E) B16F10-OVA cells were irradiated in vitro
with 20 Gy or left untreated. Serum from Rag1/
mice was added to the cultures immediately after
irradiation and C3 cleavage products were
analyzed as described in (A), (n = mice 3 per
group). (E) Relative intensities were calculated
using Bio1D software.
Data in (B) are shown as the mean ± SD. *p < 0.05,
**p < 0.005, by two-way ANOVA with the Bonfer-
roni correction.C3ar1/, and C3ar1/C5ar1/ mice showed no significant
impact of radiotherapy on tumor progression, whereas BALB/c
mice did (Figures 2B, 2C, and S2F). To avoid the issue of inherent
different tumor growth rates in various genetically ablated
strains, we blocked C3aR with an antagonist (C3aRA,
SB290157) or C5aR with a monoclonal antibody (20/70) (Baelder
et al., 2005) just before applying radiotherapy to tumor-bearing
C57BL/6 mice. This treatment blocked the improved antitumor
effect of radiotherapy (Figures 2D and S2G), which is in line
with the results observed in C3/, C3ar1/, C5ar1/, and
C3ar1/C5ar1/ mice. These data suggest that radiotherapy
induces the intratumoral generation of anaphylatoxins, which
are crucial to the therapeutic efficacy.
Radiotherapy-Induced Cell Death Locally Activates
Complement
Despite the fact that complement deposition was observed in
the vicinity of blood vessels, we failed to detect activated
complement in serum irrespective of whether mice received
radiotherapy or bore a tumor (Figure 4A). This excludes that770 Immunity 42, 767–777, April 21, 2015 ª2015 Elsevier Inc.radiotherapy or a local tumor results in
systemic activation of complement. Local
radiotherapy results in apoptosis (Wang,
2008), mitotic catastrophe, and necrosis
(Eriksson and Stigbrand, 2010), all of
which can be potent activators of comple-
ment (Basu et al., 2000; Kemper et al.,2008; Markiewski and Lambris, 2007). We first evaluated the
possibility of direct complement activation by radiation and
exposed serum from C57BL/6 or C3/ mice in vitro to a single
dose of 20 Gy or left them untreated and analyzed sera 4 and
24 hr after irradiation by immuno-blot. We did not detect any sig-
nificant changes upon irradiation (data not shown). To investi-
gate whether irradiated tumor cells can activate complement,
we either or not exposed B16F10-OVA cells in vitro to a single
dose of 20 Gy. Immediately after irradiation, 10-fold diluted
serum from C57BL/6 mice or C3/ mice was added to irradi-
ated or untreated B16F10-OVA cells. Complement activation
was detected in the supernatants 24 hr after radiation. Because
the culture serum was from C3/mice, the complement should
have been derived from the tumor cells (Figures 3A and 3B).
To identify the mode of tumor cell death upon a single dose of
20 Gy, we performed electron microscopy (EM) on B16F10-OVA
tumors isolated at different time points after radiotherapy as indi-
cated (Figure 3C). The tissue isolated before radiation showed
normal nuclei, cell boundaries, intracellular organelles, and me-
lanosomes (the dark vesicular structures) illustrating healthy
Figure 4. Radiotherapy-Induced, Tumor-Associated Complement Is
Mainly Liver-Derived but Partially Produced Locally
(A) Measurement of complement activation by immuno-blot in pooled blood
samples from naive, tumor-bearing, and irradiated tumor-bearing mice (24 hr
after radiotherapy), (n = 3 mice per group). C3 cleavage products were de-
tected using a polyclonal anti-C3 antibody. Radiotherapy, RT.
(B and C) Bone-marrow chimeras were injected with B16F10-OVA cells and
received radiotherapy 13 days later. Tumors were collected 24 hr after
radiotherapy (B) Immunofluorescence of irradiated and untreated tumors.
Sections were stained with an antibody recognizing C3b, iC3b, and C3c
(green), CD31 for blood vessels (red) and DAPI (blue). Scale bars represent
100 mm. Representative images from two independent experiments are shown
(n = 4 mice per group). (C) C3 cleavage products in the tumors were analyzed
by immuno-blot using a polyclonal anti-C3 antibody, (n = 3 mice per group).
Relative expression measured by Bio-1D software. Representative data from
two independent experiments are shown.
Data in (C) are shown as the mean ± SD. *p < 0.05, ***p < 0.0005 by two-way
ANOVA with the Bonferroni correction.tumor tissue. Already 1 hr after radiation, the first signs of radia-
tion damagewere detected in the formof extensive vacuolization
of tumor cells with normal nuclei and cell boundaries. Already
4 hr after radiation, cell boundaries were dissolved and cellular
content fragmented. Mitochondrial structures (M) were swollen
and did not show normal cristae. This did not change any further
between 4 and 18 hr after radiotherapy. We did not observe any
nuclear fragmentation and apoptotic bodies; rather, the irradi-
ated tissue showedmarked fields of necrosis withmany intracel-
lular materials now entering the extracellular space.
Because immunoglobulin M (IgM) binds to necrotic cells,
which results in complement activation (Ciurana et al., 2004;Quartier et al., 2005), we performed the experiment described
above using serum from Rag1/ mice. We observed reduced
complement activation in supernatants containing Rag1/
serum (Figures 3D and 3E), suggesting that IgM binding to
necrotic cells contributes to radiotherapy-induced complement
activation. This suggests that necrotic tumor cells express or
secrete factors that activate complement.
Microenvironmental Complement Is Produced by
Immune Cells
Hepatocytes are the main source of complement proteins,
but also extra-hepatic tissues and immune cells can produce
them (Farrar and Sacks, 2014; Kolev et al., 2014; Pio et al.,
2014; Strainic et al., 2008). To define the source of radio-
therapy-induced, tumor-associated complement, we generated
C3//WT, WT/C3/, WT/WT, and C3//C3/ bone
marrow chimeras. B16F10-OVA bearing chimeras received
radiotherapy or not and tumors were processed 24 hr later.
We detected high amounts of activated complement in
C3//WT and WT/WT mice and less in WT/C3/ mice.
The low amount of complement detected in irradiated tumors
in C3//C3/ mice is presumably tumor-derived (Figures
4B and 4C). This is in agreement with the detection of basal
expression of complement-related transcripts in cultured
B16F10-OVA tumor cells and an increased release of comple-
ment proteins by B16F10-OVA cells upon in vitro irradiation
(Figures 3A, 3B, and 4C). These experiments suggest that a large
fraction of radiotherapy-induced, tumor-associated comple-
ment is produced systemically, with a contribution of local pro-
duction by immune and tumor cells.
Radiotherapy-Induced DC Activation Depends on
Anaphylatoxins
Because several immune cells can produce complement com-
ponents (Li et al., 2007; Strainic et al., 2008), which are essential
for full functional development of antigen-presenting cells (APCs)
and T cell responses (Peng et al., 2009; Strainic et al., 2008), we
investigated which immune cells produce complement or ana-
phylatoxin receptors in irradiated tumors. We sorted DCs,
CD8+ T cells, CD4+ T cells, and other CD45.2+ cells from irradi-
ated and untreated tumors (Figure S3A) and quantified the com-
plement factor related transcripts C3, C1s, Masp2, Cfb, C3ar1,
and C5ar1 by qPCR. Because the impact of radiotherapy on
tumor-associated DCs and T cells is apparent after 24 hr and
5–7 days, respectively (Gupta et al., 2012), we harvested tumors
at these time points after radiotherapy exposure. DCs showed
increased expression of C3, Cfb, C3ar1, and C5ar1 24 hr and
168 hr after radiotherapy (Figure 5A). We failed to detect expres-
sion of C1s and Masp2 transcripts by DCs. The other CD45.2+
cells (mainly containing macrophages) showed upregulated
C5ar1 but no other complement-related transcripts at 168 hr
after radiotherapy (Figure S3B).
Recent studies demonstrate that complement factors, in
particular anaphylatoxins, directly bind to their receptors on
DCs thereby supporting their maturation, which then induces
T cell effector activation (Li et al., 2007; Peng et al., 2009; Strainic
et al., 2008). Furthermore, we showed previously that radio-
therapy-induced activation of tumor-associated dendritic cells
locally supports the function of tumor-specific CD8+ T cellsImmunity 42, 767–777, April 21, 2015 ª2015 Elsevier Inc. 771
Figure 5. Radiotherapy Induces Upregula-
tion of Transcripts for Complement and
Anaphylatoxins Receptors by DCs and Is
Essential to Their Maturation
(A) Mice were injected with B16F10-OVA cells and
received radiotherapy 12 days later. DCs (CD45.2+
TCRb CD11c+ MHC-IIhigh gated on live singlets)
were sorted from untreated and irradiated tumors
24 and 168 hr after radiotherapy. Complement-
related transcripts were quantified by qPCR (n = 5
mice per group). Radiotherapy, RT.
(B) Control and C3/ mice were injected with
B16F10-OVA cells and received radiotherapy
12 days later. CD70 and CD86 expression on
tumor-associated DCs in irradiated (48 hr after
radiotherapy) and untreated tumors plotted as
geometric mean fluorescence intensity (gMFI).
(C) BALB/c, C3ar1/, and C5ar1/ mice were
injected with CT26 cells and received radiotherapy
12 days later. DCs were analyzed as described
in (B).
(B and C) Each symbol represents an individual
mouse. Pooled data from two independent ex-
periments are shown. Data are shown as the
mean ± SD. *p < 0.05, **p < 0.005, ***p < 0.0005 by
two-way ANOVA with the Bonferroni correction.
See also Figure S3.and that this is crucial to therapeutic efficacy (Gupta et al., 2012).
Therefore, we analyzed the activation status of DCs upon irradi-
ation in C3/ and in C57BL/6 mice 2 days after radiotherapy.
DCs were equally present in untreated and irradiated tumors of
complement-proficient and -deficient mice, however, DC activa-
tion as measured by surface expression of CD70 and CD86 (Kel-
ler et al., 2008) was observed only in irradiated C57BL/6, but not
in C3/ mice (Figure 5B). These results were confirmed using
C3ar1/, C5ar1/, and BALB/c mice (Figure 5C). Thus, radio-
therapy induces upregulation of anaphylatoxins, and their recep-
tors in tumor-associated DCs controls radiotherapy-induced DC
activation.
Radiotherapy-Induced CD8+ T Cell Activation Depends
on Anaphylatoxins
T cells express complement components and anaphylatoxin re-
ceptors that are critical to T cell co-stimulation (Liszewski et al.,
2013; Strainic et al., 2008). CD8+, but not CD4+ T, cells upregu-
lated C3 and the anaphylatoxin receptors slowly at 168 hr, but
not at 24 hr, after radiotherapy (Figures 6A and S3C), whereas
C1s andMasp2were undetectable. C5aR1 and C3aR1 signaling
during cognate interaction between DCs and CD4+ T cells pro-
motes IFN-g production (Liu et al., 2008) and counteracts the
development of FoxP3+ regulatory T cells (Strainic et al., 2013).
We therefore analyzed the impact of radiotherapy on expression
of Ifng and Foxp3 and observed a strong upregulation of
Ifng in CD8+ T cells 168 hr after the treatment (Figure 6A),
but no changes of Foxp3 within the CD4+ T cell compartment
(data not shown).
To investigate the in vivo relevance of those observations,
we analyzed the infiltrate in tumors from BALB/c and
C3ar1/C5ar1/ mice by flow cytometry 168 hr after radio-
therapy. Radiotherapy resulted in higher numbers of CD45.2+772 Immunity 42, 767–777, April 21, 2015 ª2015 Elsevier Inc.and CD8+ T cells in tumors, which was independent of anaphy-
latoxins (Figure 6B). Radiotherapy had no effect on CD4+ T cell
numbers (Figures 6C and 6D). Therefore, it is unlikely that ana-
phylatoxins act as chemoattractants for T cells. We analyzed
the global IFN-g production by tumor-infiltrating CD8+ T cells
in situ. Therefore, we injected mice with Brefeldin A 4 hr
before euthanasia and measured intracellular IFN-g without
in vitro restimulation. IFN-g production by CD8+ T cells was
significantly increased in irradiated tumors in BALB/c, but not
C3ar1/C5ar1/ mice compared to untreated controls (Fig-
ures 6C, S4A, and S4B). This presumably involves anaphyla-
toxin-mediated DC maturation (Strainic et al., 2013), although a
direct activity of anaphylatoxins on CD8+ T cells cannot
be excluded. In agreement with earlier data (Strainic et al.,
2013), we observed higher numbers of FoxP3+ T cells in
C3ar1/C5ar1/ mice independent of radiotherapy (Figures
6D, S4C, and S4D). Flow cytometry results thus confirmed the
qPCR data on sorted cells (Figure 6A). We obtained similar
results using B16F10-OVA-bearing C57BL/6 mice in which
C3aR1 and C5aR1 were blocked (Figure S4E). A recent pub-
lication shows that blocking C3 improves the efficacy of fraction-
ated radiotherapy given as multiple daily fractions of 1.5 Gy
(Elvington et al., 2014), which is an apparent controversy with
our findings. We found that 53 1.5 Gy equally diminished tumor
growth as 13 20 Gy did. However, in contrast to a single high
dose, 53 1.5 Gy resulted in prolonged activation of complement
and did not support accumulation of CD8+ T cells nor their func-
tion in the tumor (Figures S4G–S4I).
To generate a complete immune cell profile related to
irradiation responses, we analyzed CD19+ B cells and found
low numbers (Figure S4F), regardless of radiotherapy or
blockade of C5aR1 and C3aR1. Tumors contained substantial
numbers of NK1.1+ cells that significantly increased upon
Figure 6. Radiotherapy Induces Upregulation of Transcripts for
Complement and Anaphylatoxins Receptors by CD8+ T Cells and
Supports Tumor-Specific Immunity
(A) C57BL/6 mice were injected with B16F10-OVA cells and received radio-
therapy 12 days later. CD8+ T cells (CD45.2+ TCRb+ CD8+ gated on live sin-
glets) were sorted from untreated and irradiated tumors 24 and 168 hr after
radiotherapy. Complement-related transcripts were quantified by qPCR (n = 5
mice per group). Radiotherapy, RT.
(B–D) BALB/c and C3ar1/C5ar1/ mice were injected with CT26 cells and
received radiotherapy 12 days later. Flow cytometric analysis was performed
7 days after radiotherapy. (B) The total number of infiltrating leukocytes
(CD45.2+), (C) CD8+ cells (left panel), and CD8+ T cells that produce IFN-g
in vivo (right panel), (D) CD4+ (left panel) and FoxP3+ CD4+ T cells (right panel)
were determined per gram tumor tissue. Mice were injected with Brefeldin A
4 hr before euthanasia.
Each symbol represents an individual mouse. Data are shown as the mean ±
SD. *p < 0.05, **p < 0.005, ***p < 0.0005 by two-way ANOVA with the Bon-
ferroni correction. See also Figure S4.
Figure 7. Dexamethasone Inhibits Complement Activation and
Reduces the Clinical Efficacy of Radiotherapy
(A–C) Mice were injected with B16F10-OVA cells and received radiotherapy
14 days later. DEX (0.3 mg/kg) was injected daily from day 12 until day 22,
(n = 6 mice per group). (A) Immunofluorescence of irradiated (24 hr) and
untreated tumors. Sections were stained with an antibody recognizing C3b,
iC3b, and C3c (green), CD31 for blood vessels (red), and DAPI (blue). Scale
bars represent 100 mm. Representative images are shown. (B) C3 cleavage
products in the tumors 24 hr after radiotherapy were analyzed by immuno-blot
using a polyclonal anti-C3 antibody. Relative expression measured by Bio-1D
software. Representative data are shown. (C) Tumor growth curves.
The data are shown as the mean ± SD. *p < 0.05 by two-way ANOVA with the
Bonferroni correction. Radiotherapy, RT.radiotherapy and seemed independent of anaphylatoxin recep-
tor blockade. We observed very low numbers of NKp46+ cells
that remained similar in all four groups (Figure S4F). Thus,
following a single dose of 20 Gy, the DC-CD8-arm of the im-
mune system appears to be selectively activated in irradiated
tumors, which is essential for tumor control and depends on
complement.Dexamethasone (DEX) is a glucocorticoid with anti-inflamma-
tory and immunosuppressive properties (Auphan et al., 1995). In
addition, it inhibits the activation of complement (Engelman
et al., 1995; Packard and Weiler, 1983). Given the important
role of complement in promoting adaptive immunity and sup-
porting the efficacy of radiotherapy, we treated mice with DEX
starting 1 day before radiotherapy. DEX treatment significantly
reduced the extent of local complement activation (Figure 7A)
and importantly, also the efficacy of radiotherapy (Figures 7B
and 7C).
Thus, radiotherapy-induced, local production of anaphylatox-
ins is essential to activation of DCs and protective effector
function of CD8+ T cells in the tumor and as such to therapeutic
efficacy.Immunity 42, 767–777, April 21, 2015 ª2015 Elsevier Inc. 773
DISCUSSION
In this study, we have demonstrated that radiotherapy induces
an acute and transient local activation of complement, which is
pivotal for tumor-specific immunity and therapeutic efficacy.
Complement has traditionally been considered only to ‘‘comple-
ment’’ the action of the immune system in the antibody-mediated
defense against pathogens. The current appreciation is that
complement is involved in many different pathological pro-
cesses such as transplant rejection, autoimmunity, neurodegen-
eration, and cancer.
The role of complement in cancer is still confusing as the pro-
duction of complement-inhibiting proteins by tumor cells or
stroma has been suggested to promote tumor growth (Kolev
et al., 2011), whereas it is also proposed that complement in
the context of chronic inflammation promotes tumor growth,
migration and angiogenesis (Markiewski et al., 2008; Pio et al.,
2014). This is in line with a previous publication (Elvington
et al., 2014) showing increased efficacy of fractionated radio-
therapy when C3 was blocked. Repeated irradiation might thus
induce a chronic inflammatory response that interferes with pro-
tective adaptive immunity. In addition, the infiltrating T cells
might be killed by the next dose before they could execute their
anti-tumor effect. A different radiotherapy protocol that either
introduces a radiotherapy holiday of 7–10 days between the frac-
tions of radiotherapy or provides a single high-dose of radio-
therapy might be required to optimally support tumor-specific
immunity (Favaudon et al., 2014).
Pathogen- and damage-associated molecular patterns can
activate C1q, MBL, and the alternative complement pathway.
The latter can also be activated by spontaneous hydrolysis of
C3 or by non-complement proteins (Markiewski and Lambris,
2007). Furthermore, modified membranes of late apoptotic and
necrotic cells are potent activators of complement (Ricklin
et al., 2010). In fact, every disturbance of homeostasis or assault
might result in activation of complement (Kolev et al., 2014). Our
data suggest that factors released from necrotic tumor cells
upon radiotherapy are responsible for local complement activa-
tion. The leakiness of tumor-associated blood vessels (Carmeliet
and Jain, 2011) might further promote accumulation of comple-
ment in the tumor.
The liver is the main source of complement, but many comple-
ment components can be produced by a variety of tissues and
immune cells either constitutively or in response to stress (Kolev
et al., 2014; Li et al., 2007). For example, locally produced C1q
contributes to removal of apoptotic material and immune com-
plexes (Roumenina et al., 2011) and supports T cell responses
(Baudino et al., 2014). We have shown here that tumor-associ-
ated T cells, DCs, other CD45+ cells, as well as tumor cells can
be a source of anaphylatoxins and their receptors in response
to radiotherapy. It is plausible to consider that tumor-associated
stroma might also contribute to the production of complement
upon radiotherapy.
Sensing immune cell-derived complement during cognate in-
teractions between T cells and DCs is essential for development
of protective immunity (Lalli et al., 2007; Liszewski et al., 2013;
Peng et al., 2009; Strainic et al., 2008). Moreover, when signaling
through C3aR1 and C5aR1 is prevented during cognate interac-
tions, CD4+ T cells develop into FoxP3+ regulatory T (Treg) cells774 Immunity 42, 767–777, April 21, 2015 ª2015 Elsevier Inc.instead of effectors (Strainic et al., 2013), in line with our obser-
vation that tumors contained more Treg cells in the absence of
anaphylatoxin receptor signaling. We found that tumor-associ-
ated DCs produced complement factors and upregulated the
expression of C3aR1 and C5aR1 upon radiotherapy, which
appeared to be essential for radiotherapy-induced DCs matura-
tion. It has been shown that anaphylatoxins directly can induce
DC maturation in vitro and that C3 upregulation precedes the
expression of IL-1, IL-12, and IL-23 (Strainic et al., 2008), sug-
gesting a direct effect of anaphylatoxins on DCs. DC maturation
is crucial to development and/or maintenance of T cell effector
function within the tumor and efficacy of radiotherapy (Gupta
et al., 2012), and indeed, tumor-infiltrating CD8+ T cells failed
to produce IFN-g after radiotherapy in the absence of signaling
through C3aR1 and C5aR1.
Given the importance of complement activation and immune
response following local radiotherapy, the administration of glu-
cocorticoids, anti-inflammatory, and immunosuppressive drugs
for managing post-radiation symptoms (Hempen et al., 2002;
Hughes et al., 2005) might have a modulating impact on the effi-
cacy of radiotherapy. Indeed, DEX given around the time of
radiotherapy significantly diminishes its efficacy, suggesting
that treatment with glucocorticoids or other anti-inflammatory
or immunosuppressive drugs might decrease the clinical
response of cancer patients to radiotherapy.
The stimulation of tumor-specific immunity by standard thera-
pies including radio- and chemotherapy has been documented
in several publications (Formenti and Demaria, 2012; Gupta
et al., 2012; Matsumura et al., 2008; Reits et al., 2006; Sharma
et al., 2013) and this phenomenonmight actually be of great clin-
ical importance: dormant metastases are intrinsically resistant to
standard treatments that mainly target rapidly dividing cells but
might still be susceptible to immune-mediated control (Koebel
et al., 2007). The abscopal effect—a situation in which not only
the irradiated tumor but also distant lesions show a clinical
response—can be explained as such. When radiotherapy is
combined with immune stimulation by anti-CTLA-4 antibodies,
the abscopal effect becomes readily apparent (Postow et al.,
2012; Verbrugge et al., 2014).
Our data expand the role of complement in the defense
against tumors. Tumor-specific immunity is unleashed by locally
produced anaphylatoxins in response to radiotherapy that acti-
vate DCs and then CD8+ T cells for optimal tumor control
following radiotherapy.
EXPERIMENTAL PROCEDURES
Mice and Cell Lines
C57BL/6, C3/, BALB/cJ, C5ar1/, C3ar1/, and Rag1/ mice were pur-
chased from the Jackson Laboratory. C3/ mice were on a C57BL/6.129S4
background; C3ar1/ and C5ar1/ mice on a BALB/cJ background,
Rag1/ mice were on a C57BL/6 background. We generated C5ar1/
C3ar1/ mice by crossing C5ar1/ and C3ar1/ mice. All mice were bred
and maintained in specific pathogen-free facilities at the University of Zurich
and University Hospital of Zurich. C57BL/6 / C3/, C3/ / C57BL/6,
C3/ / C3/, and C57BL/6 / C57BL/6 bone-marrow chimeras were
generated as previously described (Probst et al., 2003). All experiments
were performed with age- and sex-matched mice in accordance with the
guidelines of the Swiss federal and cantonal laws on animal protection.
B16F10 melanoma cells (ATCC) and B16F10-OVA (B16F10 stably trans-
fected to express chicken ovalbumin as neo-antigen, provided by Melody
Swartz, EPFL) were cultured in Dulbecco’s modified Eagle’s medium (DMEM,
GIBCO Invitrogen), CT26 murine colon carcinoma (ATCC) cells in MEM
medium (Invitrogen). Media were supplemented with 10% fetal calf serum,
5 3 105 M 2-mercaptoethanol, 10 mM sodium pyruvate 2 mM L-glutamine,
and antibiotics.
In Vivo Experiments
23 105 B16F10-OVA, B16F10 or CT26 were injected s.c. in 100 ml of a 1:1 mix
of PBS and Matrigel Basement Membrane Matrix (BD Biosciences).
Local radiotherapy with a single dose of 20 or 5 Gy was performed at indi-
cated time points using a Xstrahl 200 kV X-ray unit at 1 Gy/min as described
(Gupta et al., 2012). Prior to radiotherapy, mice were anaesthetized by i.p. in-
jection of 50 mg/kg ketamine and 10 mg/kg xylazine.
The C3aR1 antagonist (C3aRA) N2-[(2,2-Diphenylethoxy)acetyl]-L-arginine
(SB290157, Calbiochem) was administered i.p. at 2 mg/kg body weight in
100 ml PBS. Anti-C5aR1 mAb 20/70 (Hycult Biotech) or an isotype control
(rat IgG2b anti-HLA-DR, clone SFRF8B6) was administered i.p. at 0.6 mg/kg
in 100 ml PBS (Baelder et al., 2005; Godau et al., 2004; Sun et al., 2011).
C3aRA and anti-C5aR1 mAb were administered every second day starting
at the day of radiotherapy until the end of the experiment.
To measure the cytokine production in vivo, we injected Brefeldin A (BFA,
Sigma-Aldrich). A 20-mg/ml stock was prepared in DMSO. Further dilution
to 0.5 mg/ml was made in PBS, and 500 ml was injected i.p. 4 hr before
mice were sacrificed (Liu andWhitton, 2005). DEX (Sigma-Aldrich) was admin-
istered daily at 0.3 mg/kg in PBS p.o., starting 1 day before radiotherapy.
Tumors were measured with a caliper every 2–3 days in two dimensions
(length and width). Excised tumors were weighed and processed for flow
cytometry, histology, or isolation of RNA and proteins.
In Vitro Experiments
C57BL/6 and C3/ mice were bled from the sublingual vein and sera were
collected with Microtainer SST tubes (BD). Sera were diluted 1:10 with PBS,
irradiated with 20 Gy (YXLON Y.SMART582, YXLON International GmbH,
Hamburg, D) and subsequently incubated at 37C. B16F10-OVA cells were
cultured in 6-well plates (106 cells per well) and irradiated as described above.
Immediately after irradiation, 60 ml of serum from C57BL/6 or C3/ mice
diluted in 500 ml of PBS was added to the cells. Control samples were not
irradiated but treated similarly otherwise. Supernatants were taken 4 hr and
24 hr after irradiation and were stored at 80C until further use.
Human Samples
Two sets of biopsies were provided by the Department of Dermatology, Uni-
versity Hospital Zurich. Patients signed informed consent. The ethical commit-
tee of the canton of Zurich approved this study (EK647). (1) Paired biopsies
were collected from two patients with basal cell carcinoma and one with
lentigo maligna melanoma immediately before and 24–36 hr after radiotherapy
(1.5–2 Gy) and were snap frozen. (2) Four biopsies were collected from four
patients (two with basal cell carcinoma, one with melanoma, and one with
squamous cell carcinoma) 24–36 hr after radiotherapy (1.5–2 Gy) but without
previous interventions and were snap frozen.
Statistical Analysis
Results are presented as mean ± SD. Statistical significance was determined
by ANOVA using GraphPad Prism 5 software (GraphPad). When multiple
groups were compared, we used the Bonferroni post-test correction. When
two groups were compared, we used the two-tailed Student’s t test. *, p <
0.05; **, p < 0.01; ***, p < 0.001.
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